NLRP3炎症小体与腹膜透析患者腹膜纤维化的研究进展

Research Progress of NLRP3 Inflammasomes and Peritoneal Fibrosis in Peritoneal Dialysis Patients

腹膜透析已逐渐成为终末期肾病患者的首选治疗方法之一,腹膜纤维化所致的超滤衰竭是患者退出腹膜透析的主要原因。Nod样受体蛋白3(NLRP3)炎症小体是一种模式识别受体,其激活可引起强效促炎因子白细胞介素(IL) 1β、IL-18的成熟和释放,在急慢性炎症反应过程及多种非感染性疾病的发生发展中发挥重要作用。NLRP3炎症小体与腹膜透析过程中的急慢性腹膜炎、腹膜纤维化的发生发展密切相关,阐明NLRP3炎症小体与腹膜透析相关腹膜纤维化的调控机制,可为腹膜纤维化的防治提供理论基础。

Peritoneal dialysis has gradually become one of the preferred treatment methods for patients with end-stage renal disease. The ultrafiltration failure caused by peritoneal fibrosis is the main reason for patients to withdraw from peritoneal dialysis. Nod-like receptor protein 3( NLRP3) inflammasome is a kind of pattern recognition receptor,and its activation can induce the maturation and release of potent proinflammatory factors interleukin( IL) 1β and IL-18,which plays an important role in the occurrence and development of acute and chronic inflammatory reactions and a variety of non-infectious diseases. In recent years,it has been found that NLRP3 inflammasome is closely related to the occurrence and development of acute and chronic peritonitis and peritoneal fibrosis in peritoneal dialysis process,so clarification of the regulatory mechanism between the NLRP3 inflammasomes and peritoneal fibrosis in peritoneal dialysis can provide a theoretical basis for the prevention and treatment of peritoneal fibrosis.